Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Clinical Immunology · Mendelian Susceptibility to Mycobacterial Disease due to Partial STAT1 Deficiency

The Biology of Your Diagnosis and Similar Conditions

At a Glance

Partial STAT1 deficiency weakens the immune signal that helps cells control mycobacteria, but some STAT1 function remains. Distinguishing it from complete deficiency, STAT1 gain-of-function, and other inherited causes helps guide testing and treatment.

To understand partial STAT1 deficiency, it helps to view your immune system as a high-speed communication network. In a healthy system, immune cells use a specific “circuit”—the IL-12/IFN-gamma pathway—to coordinate an attack against bacteria that hide inside cells, such as mycobacteria [1][2].

The Immune Circuit: A Two-Way Conversation

The conversation starts when a “scout” cell (an antigen-presenting cell) swallows a bacterium. It sends out a signal called IL-12 (interleukin-12) to call for backup [1]. In response, your “soldier” cells (T cells and Natural Killer cells) produce a powerful protein called interferon-gamma (IFN-γ) [2][3].

For this signal to work, the IFN-γ must dock onto a receiver on the surface of other cells. This docking triggers STAT1 proteins to join together, receive a “spark” (phosphorylation), and travel into the cell’s nucleus (the control center) to turn on the genes needed to kill the bacteria [4][5]. In your case, a mutation in the STAT1 gene means this final step—the actual execution of the “kill” command—is weak or delayed [6][7].

Partial vs. Complete STAT1 Deficiency

It is vital to distinguish your diagnosis from complete STAT1 deficiency, which is a far more aggressive condition.

  • Partial Deficiency (Your Diagnosis): Your STAT1 proteins still have some “residual” function. They work, just not well enough [8][6]. This usually leads to susceptibility to mycobacteria and sometimes certain viruses [9][10]. It is usually managed medically, though rarely may require escalation for severe, refractory disease.
  • Complete Deficiency: There is zero functional STAT1 protein. This shuts down almost all interferon signaling, leaving the body defenseless against many types of infections [11]. This form can be life-threatening in early childhood and often prompts consideration of a Hematopoietic Stem-Cell Transplant (HSCT), a procedure to replace the immune system [9][12].

STAT1 Gain-of-Function (GOF): A Different Challenge

You may see “STAT1” mentioned in support groups for people with chronic yeast infections (thrush). This is a different condition called STAT1 Gain-of-Function [13]. In GOF, the STAT1 protein is too active or stays “turned on” for too long [14]. While your condition (loss-of-function) makes you prone to mycobacteria, GOF primarily causes chronic mucocutaneous candidiasis (persistent fungal infections of the skin, nails, and mouth) due to an imbalance in a different part of the immune system, though its phenotype can also include bacterial, viral, and mycobacterial infections [13][14].

Why the Exact Genetic Subtype Matters

“Partial STAT1 deficiency” is one of many genetic causes of Mendelian Susceptibility to Mycobacterial Disease (MSMD). Other genes that can cause similar symptoms include IFNGR1, IFNGR2, IL12RB1, and IL12B [15][16].

Knowing your exact genetic “zip code” is critical because it dictates your treatment:

  • Therapy Choice: Some people with mutations in the IL-12 part of the circuit respond very well to injections of recombinant IFN-gamma because their cells can still hear that signal [15][17]. However, if the “receiver” (IFNGR1/2) is completely broken, giving more IFN-gamma won’t help [18]. Because your defect is in STAT1 (downstream of the signal), adding extra IFN-gamma has uncertain and variant-dependent benefit [10].
  • Family Risk: Some forms (like AD STAT1) can show variable penetrance, meaning one person in a family might be very sick while another with the same mutation has no symptoms at all [10][19].

By identifying that your specific issue is a “partial” defect in STAT1, your doctors can focus on the specific infections you are most likely to face while avoiding the more intensive treatments (like early transplant) required for complete deficiencies unless strictly necessary [20][9].

Common questions in this guide

How does partial STAT1 deficiency affect the immune system?
Partial STAT1 deficiency leaves some STAT1 protein activity, but the response to interferon-gamma is weak or delayed. This can make it harder for immune cells to control bacteria that live inside cells, especially mycobacteria, and may increase susceptibility to some viruses.
How is partial STAT1 deficiency different from complete STAT1 deficiency?
Partial deficiency retains residual STAT1 function, whereas complete deficiency has little or no functional STAT1. Complete deficiency can cause much broader and more severe infections, often early in life, and may lead doctors to consider a hematopoietic stem-cell transplant; partial deficiency is usually managed medically.
Is STAT1 gain-of-function the same as partial STAT1 deficiency?
No. STAT1 gain-of-function means the protein is overactive or remains switched on too long, while partial STAT1 deficiency is a loss-of-function problem. Gain-of-function is classically linked to chronic mucocutaneous candidiasis, or persistent yeast infections of the mouth, skin, or nails, although other infections can occur.
Why are other genes tested when someone may have STAT1 deficiency?
Several inherited defects can produce a similar pattern of mycobacterial infections, including changes in IFNGR1, IFNGR2, IL12RB1, or IL12B. Identifying the exact gene matters because treatments that help one defect may not help another; for example, extra interferon-gamma may help some IL-12 pathway defects but may not overcome a broken receptor.
Could interferon-gamma treatment help someone with partial STAT1 deficiency?
Possibly, but the answer depends on the specific STAT1 variant and how much signaling remains. Because STAT1 is downstream of interferon-gamma, adding more of the signal has uncertain benefit in partial STAT1 deficiency and should be considered by an experienced immunology team.
Can a STAT1 deficiency variant affect other family members?
Some STAT1 deficiency forms are autosomal dominant, meaning one altered copy can be enough to cause the condition, while others are autosomal recessive. Dominant variants can have variable penetrance, so a relative may carry the same change but have few or no symptoms; genetic counseling can help assess testing for family members or future children.
What tests show how well my STAT1 protein is working?
Doctors may use tests such as STAT1 phosphorylation assays to see how immune cells respond to signaling. Depending on the variant, additional studies can assess whether STAT1 moves into the nucleus or binds DNA, helping clarify residual function.

Get notified when new evidence is published on Mendelian susceptibility to mycobacterial diseases due to partial STAT1 deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    Interleukin-12: Central Roles in Immune Regulation and Disease Therapy.

    Psoma A, van den Bogaart G

    Immunology and cell biology 2026; doi:10.1111/imcb.70167.

    PMID: 42813654
  2. 2

    Novel nonsense IL-12Rβ1 mutation associated with recurrent tuberculosis.

    Ul Akbar N, Khan SN, Amin MU, et al.

    Immunologic research 2019; (67(4-5)):408-415 doi:10.1007/s12026-019-09094-8.

    PMID: 31741236
  3. 3

    Impaired IFNγ-Signaling and Mycobacterial Clearance in IFNγR1-Deficient Human iPSC-Derived Macrophages.

    Neehus AL, Lam J, Haake K, et al.

    Stem cell reports 2018; (10(1)):7-16 doi:10.1016/j.stemcr.2017.11.011.

    PMID: 29249666
  4. 4

    Disseminated Tuberculosis and Chronic Mucocutaneous Candidiasis in a Patient with a Gain-of-Function Mutation in Signal Transduction and Activator of Transcription 1.

    Pedraza-Sánchez S, Lezana-Fernández JL, Gonzalez Y, et al.

    Frontiers in immunology 2017; (8()):1651 doi:10.3389/fimmu.2017.01651.

    PMID: 29270166
  5. 5

    Two novel STAT1 mutations cause Mendelian susceptibility to mycobacterial disease.

    Liu Z, Zhou M, Yuan C, et al.

    Biochemical and biophysical research communications 2022; (591()):124-129 doi:10.1016/j.bbrc.2021.11.036.

    PMID: 34815077
  6. 6

    Genetic and Functional Identifying of Novel STAT1 Loss-of-Function Mutations in Patients with Diverse Clinical Phenotypes.

    Chen X, Chen J, Chen R, et al.

    Journal of clinical immunology 2022; (42(8)):1778-1794 doi:10.1007/s10875-022-01339-w.

    PMID: 35976469
  7. 7

    A novel STAT1 loss-of-function mutation associated with Mendelian susceptibility to mycobacterial disease.

    Ye F, Zhang W, Dong J, et al.

    Frontiers in cellular and infection microbiology 2022; (12()):1002140 doi:10.3389/fcimb.2022.1002140.

    PMID: 36339330
  8. 8

    Inborn errors of STAT1 immunity.

    Mizoguchi Y, Okada S

    Current opinion in immunology 2021; (72()):59-64 doi:10.1016/j.coi.2021.02.009.

    PMID: 33839590
  9. 9

    Genetic, Immunological, and Clinical Features of 32 Patients with Autosomal Recessive STAT1 Deficiency.

    Le Voyer T, Sakata S, Tsumura M, et al.

    Journal of immunology (Baltimore, Md. : 1950) 2021; (207(1)):133-152 doi:10.4049/jimmunol.2001451.

    PMID: 34183371
  10. 10

    Novel STAT1 Variants in Japanese Patients with Isolated Mendelian Susceptibility to Mycobacterial Diseases.

    Ono R, Tsumura M, Shima S, et al.

    Journal of clinical immunology 2023; (43(2)):466-478 doi:10.1007/s10875-022-01396-1.

    PMID: 36336768
  11. 11

    Autosomal recessive complete STAT1 deficiency caused by compound heterozygous intronic mutations.

    Sakata S, Tsumura M, Matsubayashi T, et al.

    International immunology 2020; (32(10)):663-671 doi:10.1093/intimm/dxaa043.

    PMID: 32603428
  12. 12

    Hematopoietic Stem Cell Transplantation for Patients with Autosomal Recessive Complete INF-λ Receptor 2 Deficiency: Experience in Oman.

    Nazir HF, Rawas AA, Tamemi SA, et al.

    Transplantation and cellular therapy 2021; (27(10)):881.e1-881.e5 doi:10.1016/j.jtct.2021.07.013.

    PMID: 34293519
  13. 13

    Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype.

    Toubiana J, Okada S, Hiller J, et al.

    Blood 2016; (127(25)):3154-64 doi:10.1182/blood-2015-11-679902.

    PMID: 27114460
  14. 14

    Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy.

    Okada S, Asano T, Moriya K, et al.

    Journal of clinical immunology 2020; (40(8)):1065-1081 doi:10.1007/s10875-020-00847-x.

    PMID: 32852681
  15. 15

    Mendelian susceptibility to mycobacterial diseases: State of the puzzle.

    Errami A, Bousfiha AA

    Qatar medical journal 2023; (2023(2)):25 doi:10.5339/qmj.2023.sqac.25.

    PMID: 38025345
  16. 16

    Mendelian susceptibility to mycobacterial disease: IFN-γ-driven immunity collapse underlies heterogeneous infections.

    Qian M, Zhou J, Zhou Q, et al.

    Frontiers in immunology 2026; (17()):1781297 doi:10.3389/fimmu.2026.1781297.

    PMID: 42183200
  17. 17

    Mendelian Susceptibility to Mycobacterial Disease due to IL-12Rβ1 Deficiency in Three Iranian Children.

    Sarrafzadeh SA, Mahloojirad M, Nourizadeh M, et al.

    Iranian journal of public health 2016; (45(2)):249-54.

    PMID: 27114990
  18. 18

    Hematopoietic stem cell gene therapy for IFNγR1 deficiency protects mice from mycobacterial infections.

    Hetzel M, Mucci A, Blank P, et al.

    Blood 2018; (131(5)):533-545 doi:10.1182/blood-2017-10-812859.

    PMID: 29233822
  19. 19

    The Child with Recurrent Mycobacterial Disease.

    Reed B, Dolen WK

    Current allergy and asthma reports 2018; (18(8)):44 doi:10.1007/s11882-018-0797-3.

    PMID: 29936646
  20. 20

    Clinical recommendations for diagnosis and management of Mendelian susceptibility to mycobacterial disease in resource-limited settings.

    Cornelissen H, Glanzmann B, van Coller A, et al.

    The journal of allergy and clinical immunology. Global 2025; (4(4)):100540 doi:10.1016/j.jacig.2025.100540.

    PMID: 41048447

This page explains the immune biology and related conditions behind partial STAT1 deficiency for educational purposes. It does not replace medical advice; discuss genetic results, infection prevention, and treatment choices with an immunologist or other qualified clinician.

Guide contents Mendelian susceptibility to mycobacterial diseases due to partial STAT1 deficiency
Research & Literature
02 Watching for Symptoms and Knowing When to Act 04 Medical Testing and Understanding Your Reports